fig3
![MRI for screening and surveillance for hepatocellular cancer in NAFLD and NASH](https://image.oaes.cc/33f89a0b-e3ea-441f-860a-c9de2554ab2e/5775.fig.3.jpg)
Figure 3. HCC in a patient with NASH using EOVIST, HBP agent. Non-contrast image cirrhotic liver with a low signal intensity mass; The arterial phase shows a vague non-rim enhancement; Portal venous phase with subtle washout; Transitional phase; HBP with clear washout.